title: Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancer.
abstract: PURPOSE Conventional medicine has had little to offer patients with inoperable pancreatic adenocarcinoma; thus, many patients seek alternative treatments. The National Cancer Institute, in 1998, sponsored a randomized, phase III, controlled trial of proteolytic enzyme therapy versus chemotherapy. Because most eligible patients refused random assignment, the trial was changed in 2001 to a controlled, observational study. METHODS All patients were seen by one of the investigators at Columbia University, and patients who received enzyme therapy were seen by the participating alternative practitioner. Of 55 patients who had inoperable pancreatic cancer, 23 elected gemcitabine-based chemotherapy, and 32 elected enzyme treatment, which included pancreatic enzymes, nutritional supplements, detoxification, and an organic diet. Primary and secondary outcomes were overall survival and quality of life, respectively. Results At enrollment, the treatment groups had no statistically significant differences in patient characteristics, pathology, quality of life, or clinically meaningful laboratory values. Kaplan-Meier analysis found a 9.7-month difference in median survival between the chemotherapy group (median survival, 14 months) and enzyme treatment groups (median survival, 4.3 months) and found an adjusted-mortality hazard ratio of the enzyme group compared with the chemotherapy group of 6.96 (P < .001). At 1 year, 56% of chemotherapy-group patients were alive, and 16% of enzyme-therapy patients were alive. The quality of life ratings were better in the chemotherapy group than in the enzyme-treated group (P < .01). CONCLUSION Among patients who have pancreatic cancer, those who chose gemcitabine-based chemotherapy survived more than three times as long (14.0 v 4.3 months) and had better quality of life than those who chose proteolytic enzyme treatment.
authors.affiliation: Columbia University Mailman School of Public Health, 722 W 168th St, Rm 734, New York, NY 10032, USA.
authors.forename: John A
authors.initials: JA
authors.lastname: Chabot
authors.forename: Wei-Yann
authors.initials: WY
authors.lastname: Tsai
authors.forename: Robert L
authors.initials: RL
authors.lastname: Fine
authors.forename: Chunxia
authors.initials: C
authors.lastname: Chen
authors.forename: Carolyn K
authors.initials: CK
authors.lastname: Kumah
authors.forename: Karen A
authors.initials: KA
authors.lastname: Antman
authors.forename: Victor R
authors.initials: VR
authors.lastname: Grann
mesh_terms: D000230:Adenocarcinoma / Q000178:diet therapy / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000529:Complementary Therapies / Q000009:adverse effects; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D019587:Dietary Supplements / Q000009:adverse effects; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000178:diet therapy / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D010447:Peptide Hydrolases / Q000009:adverse effects / Q000627:therapeutic use*; D016016:Proportional Hazards Models; D011788:Quality of Life; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D010447:Peptide Hydrolases; D000093542:Gemcitabine
references.citation: Semin Oncol. 2005 Aug;32(4 Suppl 6):S1-3
references.pmid: 16143160
references.citation: Zhong Xi Yi Jie He Xue Bao. 2006 Sep;4(5):455-66
references.pmid: 16965737
references.citation: N Engl J Med. 2000 Jun 22;342(25):1907-9
references.pmid: 10861329
references.citation: J Natl Cancer Inst. 2002 Sep 4;94(17):1275-81
references.pmid: 12208892
references.citation: Clin Adv Hematol Oncol. 2003 Jul;1(7):430-4
references.pmid: 16258429
references.citation: J Clin Oncol. 2001 Sep 15;19(18 Suppl):55S-60S
references.pmid: 11560974
references.citation: N Engl J Med. 2000 Jun 22;342(25):1887-92
references.pmid: 10861325
references.citation: Biometrics. 1985 Mar;41(1):103-16
references.pmid: 4005368
references.citation: Nutr Cancer. 1999;33(2):117-24
references.pmid: 10368805
references.citation: J Clin Oncol. 1997 Jun;15(6):2403-13
references.pmid: 9196156
references.citation: J Clin Oncol. 1995 Mar;13(3):748-55
references.pmid: 7884435
references.citation: Clin Cancer Res. 2002 May;8(5):935-42
references.pmid: 12006504
references.citation: Cancer Chemother Pharmacol. 2008 Jan;61(1):167-75
references.pmid: 17440727
references.citation: Ann Intern Med. 1997 Oct 15;127(8 Pt 2):757-63
references.pmid: 9382394
references.citation: JAMA. 2005 Feb 23;293(8):1001-3
references.pmid: 15728172
references.citation: J Clin Oncol. 2003 Sep 15;21(18):3402-8
references.pmid: 12885837
references.citation: J Surg Res. 2004 Mar;117(1):144-53
references.pmid: 15013725
references.citation: Semin Pediatr Infect Dis. 2004 Jan;15(1):52-7
references.pmid: 15175995
references.citation: Oncologist. 2008 May;13(5):562-76
references.pmid: 18515741
references.citation: JAMA. 2005 Feb 23;293(8):970-8
references.pmid: 15728168
references.citation: Ann Intern Med. 1950 Jan;32(1):80-115, illust
references.pmid: 15404129
references.citation: J Clin Oncol. 2007 May 20;25(15):1960-6
references.pmid: 17452677
references.citation: Integr Cancer Ther. 2007 Sep;6(3):208-34
references.pmid: 17761635
references.citation: JAMA. 2004 Mar 3;291(9):1092-9
references.pmid: 14996778
references.citation: Emerg Themes Epidemiol. 2005 Sep 01;2:8
references.pmid: 16137327
references.citation: J Natl Compr Canc Netw. 2005 Sep;3(5):627-36
references.pmid: 16194454
references.citation: J Clin Oncol. 2000 Feb;18(3):668-83
references.pmid: 10653883
references.citation: Palliat Support Care. 2003 Sep;1(3):267-73
references.pmid: 16594427
references.citation: N Engl J Med. 1994 Apr 14;330(15):1029-35
references.pmid: 8127329
references.citation: J Clin Oncol. 2005 May 20;23(15):3509-16
references.pmid: 15908661
references.citation: Surg Oncol Clin N Am. 2004 Oct;13(4):711-35, x
references.pmid: 15350944
references.citation: Support Care Cancer. 2005 Oct;13(10):806-11
references.pmid: 15711946
references.citation: BMC Complement Altern Med. 2007 Aug 04;7:25
references.pmid: 17683580
references.citation: Spine (Phila Pa 1976). 2003 Oct 1;28(19):2268-75
references.pmid: 14520043
references.citation: J Clin Oncol. 2000 Nov 1;18(21):3595-603
references.pmid: 11054432
references.citation: Qual Life Res. 2002 May;11(3):207-21
references.pmid: 12074259